Vir Biotechnology
Vir Biotechnology leverages the immune system to develop transformative medicines for infectious diseases and cancer. With advanced technology platforms like the antibody platform and PRO-XTEN™ masking technology, the company focuses on unmet medical needs such as hepatitis delta, oncology, HIV, influenza, COVID-19, and HPV. Led by an experienced leadership team and collaborating with top institutions, Vir aims to deliver impactful therapies rapidly and safely.
Industries
Nr. of Employees
large (251-1000)
Vir Biotechnology
1800 Owens Street, Suite 900, San Francisco, CA 94158, United States
Patents
Products
Combination therapeutic regimen for chronic hepatitis delta
A clinical-stage combination approach comprising a neutralizing monoclonal antibody engineered for immune engagement paired with a liver-targeted siRNA to reduce viral antigen, intended to suppress or eliminate hepatitis delta virus.
Masked protease-activated T-cell engager candidates for solid tumors
Preclinical and early clinical T-cell engager programs using protease-releasable masking technology to keep T-cell engagers inactive in circulation and activate them in the tumor microenvironment; targets include HER2, EGFR and PSMA.
Broadly neutralizing antibody programs for HIV
Preclinical antibody programs leveraging broadly neutralizing antibody approaches and Fc modification to enhance T-cell responses toward a functional cure strategy for HIV.
Monoclonal antibody candidates for influenza and COVID-19 (developmental)
Investigational monoclonal antibody candidates developed for prevention or treatment of influenza and next-generation antibodies for COVID‑19, optimized for potency, breadth and resistance to viral escape.
Therapeutic vaccine candidate using T-cell viral vector
Investigational therapeutic vaccine delivered by a viral vector intended to elicit robust T cell responses against HPV to treat precancerous lesions and clear underlying infection.
Combination therapeutic regimen for chronic hepatitis delta
A clinical-stage combination approach comprising a neutralizing monoclonal antibody engineered for immune engagement paired with a liver-targeted siRNA to reduce viral antigen, intended to suppress or eliminate hepatitis delta virus.
Masked protease-activated T-cell engager candidates for solid tumors
Preclinical and early clinical T-cell engager programs using protease-releasable masking technology to keep T-cell engagers inactive in circulation and activate them in the tumor microenvironment; targets include HER2, EGFR and PSMA.
Broadly neutralizing antibody programs for HIV
Preclinical antibody programs leveraging broadly neutralizing antibody approaches and Fc modification to enhance T-cell responses toward a functional cure strategy for HIV.
Monoclonal antibody candidates for influenza and COVID-19 (developmental)
Investigational monoclonal antibody candidates developed for prevention or treatment of influenza and next-generation antibodies for COVID‑19, optimized for potency, breadth and resistance to viral escape.
Therapeutic vaccine candidate using T-cell viral vector
Investigational therapeutic vaccine delivered by a viral vector intended to elicit robust T cell responses against HPV to treat precancerous lesions and clear underlying infection.
Services
Collaborative R&D agreements and licensing partnerships with academic, industry and government organizations to advance discovery and development programs.
Collaborative R&D agreements and licensing partnerships with academic, industry and government organizations to advance discovery and development programs.
Expertise Areas
- Antibody discovery and engineering
- AI-driven protein engineering
- Clinical trial management and operations
- T-cell engager and oncology therapeutic development
Key Technologies
- Monoclonal antibody discovery
- AI-driven antibody design and optimization
- Protease-activated masking/prodrug technology
- T-cell engager platforms